Seeking Novel Assets and Targets for Epilepsy

A mid-sized biopharmaceutical company with a leading presence in epilepsy and neuroscience is seeking both novel therapeutic assets and biological targets in epilepsy. 

Approaches of Interest:

• All forms of epilepsy, including focal, generalized, rare genetic, and drug-resistant epilepsies, and developmental and epileptic encephalopathies (e.g. Dravet syndrome) 
• Approaches aimed at seizure control and disease modification, as well as treatments for associated cognitive, sleep, or psychiatric symptoms
• Acute or rescue treatments (e.g. for seizure clusters or status epilepticus) 
• Open to modalities including small molecules, peptides, antibodies, ASOs, siRNA, and neuromodulation. Oral delivery is preferred, but all routes will be considered 
• All mechanisms of action are within scope 
• Drug repurposing opportunities are also of interest 

Out of Scope:

• Diagnostics, biomarkers, and medical devices 
• Viral gene therapy, cell therapy, and non-viral gene therapy or gene editing approaches (e.g. LNP-based delivery, CRISPR) 

Developmental Stages of Interest:

• Opportunities ranging from preclinical research through to early clinical development are within scope 
• Opportunities with in vivo validation are of highest interest, although opportunities with in vitro validation will still be considered 

Submission Information

Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. Where relevant, please highlight the indication, target and mechanism of action related to your opportunity. In submitting to this campaign, you confirm that your submission contains only non-confidential information. 

Opportunity for Collaboration

Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations.